Home Pharma China Web Edition Pharma China Archives Online Databases Subscription/Order/Info Event Calendar China Pharma Providers About Us
Location: Home > Pharma China Web Edition > Product/R&D News    
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Editorials
Commentaries
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor´s Picks
 
 
WiCON International Group
311 Sayre Drive,
Princeton, NJ 08540, USA
Tel/Fax: +1 702-9953905
Email:
info@pharmachinaonline.com

China Head Office
c/o Beijing Jicai PharmTech
Suite B-17D, Oriental Kenzo Plaza
48 Dongzhimenwai Dajie
Dongcheng District
Beijing 100027, China
Tel: +86 10 84476010
Fax: +86 10 84476010
Email:
info@pharmachinaonline.com
 
 
 
Product/R&D News
 
China-Based Ivy Capital Invests in Betagenon's Clinical Stage AMP... 1/20/2020
Ambrx and Sino Biopharma Announce Collaboration to Develop Two Ne... 1/14/2020
Chi-Med Initiates a PII Trial of Surufatinib in Combo with Toripa... 1/14/2020
NMPA Clears Phase 3 Trial for SB12, Samsung Bioepis' Biosimilar E... 1/11/2020
HK Researcher Discovers Anticancer NCE Phorbiplatin (free) 1/8/2020
Innovent and Sirnaomics Cooperate to Combine Sintilimab and RNAi ... 1/7/2020
China Approves First Indigenously-developed 13-Valent Pneumonia V... (free) 1/3/2020
China's 'Seaweed' Alzheimer's Drug Is Now Available to Patients 12/30/2019
Luye Pharma Submits New Drug Application in the U.S. for Its Anti... 12/27/2019
Bridge and Daewoong Announces NMPA Clearance of IND for BBT-401, ... 12/27/2019
Sanofi Files NDA for the World's Atopic Dermatitis Biologic Dupil... 12/26/2019
CStone Pharma to Submit NDA for Anticancer Pralsetinib Next Year 12/26/2019
BeiGene Announces Acceptance of a China sNDA for REVLIMID in Rela... 12/23/2019
Chi-Med Gets Priority Review for 'Surufatinib' in China 12/20/2019
InxMed Cleared to Initiate Phase I Trial for Anticancer FAK Inhib... 12/20/2019
Van Andel to Pay $5.5M for Failing to Disclose Chinese Funding 12/19/2019
Everest Medicines Announces Chinese Clinical Trial Approval of Ne... 12/18/2019
BeiGene's Brukinsa Fails to Match AbbVie-J&J Rival Imbruvica in L... 12/16/2019
BeiGene Announces Clinical Data on Anti-PD-1 Tislelizumab in Comb... 12/13/2019
ZJ Medicine and Ambrx Present Positive Data from a Phase 1a/1b Tr... 12/13/2019
Eli Lilly's Verzenio and Amgen's Blincyto To Be Granted Priority ... 12/12/2019
CStone's anti-PD-L1 antibody Demonstrates Promising Antitumor Act... 12/10/2019
Samsung Bioepis Approved to Initiate Phase 3 Trial of Trastuzumab... 12/9/2019
Innovent Announces First Patient Dosed in Phase I Trial of Anti-L... 12/6/2019
Amgen's IND for Osteoporosis Drug Romosozumab Approved in China 12/5/2019
XiAn Janssen's Application for 2nd Indication of Erleada Accepted... 12/5/2019
Bio-Thera's IND for Biosimilar of Stelara (Ustekinumab) Approved ... 12/4/2019
Hanmi's Chinese Partner to Start Trials for Anticancer Treatment 11/29/2019
UK and China Research Team Take First Steps Towards A Vaccine for... 11/26/2019
Chi-Med's Surufatinib Granted Orphan Drug Designation by the USFD... 11/26/2019
Page:1/4    Total number of articles:117  :[1][2][3][4]

 
 
 
 
© Wicon International Group  Support by: www.heightow.com   Site map | Contact Us | Links